Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of 3 Doses of INV-202 With an Optional Open-Label Extension in Patients With Obesity and Metabolic Syndrome
NCT05891834 is registered in ClinicalTrials.gov with Inversago Pharma Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of 3 Doses of INV-202 With an Optional Open-Label Extension in Patients With Obesity and Metabolic Syndrome
- Lead sponsor
- Inversago Pharma Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 8, 2023
- Completion date
- February 14, 2025
- Enrollment
- 243 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.